PortalPublikationenC-reactive protein flare predicts response to checkpoint inh...

C-reactive protein flare predicts response to checkpoint inhibitor treatment in melanoma

Standard

C-reactive protein flare predicts response to checkpoint inhibitor treatment in melanoma. / Kött, Julian; Zimmermann, Noah; Zell, Tim; Heidrich, Isabel; Geidel, Glenn; Rünger, Alessandra; Smit, Daniel J.; Merkle, Myriam; Parnian, Niousha; Hansen, Inga; Hoehne, Inka; Abeck, Finn; Torster, Leopold; Weichenthal, Michael; Pantel, Klaus; Schneider, Stefan W; Gebhardt, Christoffer.

in: J EUR ACAD DERMATOL, Jahrgang 38, Nr. 8, 08.2024, S. 1575–1587.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Kött, J, Zimmermann, N, Zell, T, Heidrich, I, Geidel, G, Rünger, A, Smit, DJ, Merkle, M, Parnian, N, Hansen, I, Hoehne, I, Abeck, F, Torster, L, Weichenthal, M, Pantel, K, Schneider, SW & Gebhardt, C 2024, 'C-reactive protein flare predicts response to checkpoint inhibitor treatment in melanoma', J EUR ACAD DERMATOL, Jg. 38, Nr. 8, S. 1575–1587. https://doi.org/10.1111/jdv.19941

APA

Kött, J., Zimmermann, N., Zell, T., Heidrich, I., Geidel, G., Rünger, A., Smit, D. J., Merkle, M., Parnian, N., Hansen, I., Hoehne, I., Abeck, F., Torster, L., Weichenthal, M., Pantel, K., Schneider, S. W., & Gebhardt, C. (2024). C-reactive protein flare predicts response to checkpoint inhibitor treatment in melanoma. J EUR ACAD DERMATOL, 38(8), 1575–1587. https://doi.org/10.1111/jdv.19941

Vancouver

Kött J, Zimmermann N, Zell T, Heidrich I, Geidel G, Rünger A et al. C-reactive protein flare predicts response to checkpoint inhibitor treatment in melanoma. J EUR ACAD DERMATOL. 2024 Aug;38(8):1575–1587. https://doi.org/10.1111/jdv.19941

Bibtex

@article{0149bb91c4634196bafa0d11ea31946d,
title = "C-reactive protein flare predicts response to checkpoint inhibitor treatment in melanoma",
abstract = "BACKGROUND: The treatment of melanoma has been revolutionized by the use of immune checkpoint inhibition (ICI), but many patients do not benefit. Furthermore, immune-related adverse events may occur during therapy. A predictive biomarker is needed to reliably identify patients benefitting. In lung, renal cell and bladder cancer early C-reactive protein (CRP) kinetics were shown to be a predictive biomarker for ICI.OBJECTIVE: Here, we investigate early CRP kinetics as predictive biomarker for ICI in melanoma patients.METHODS: Two independent prospectively collected cohorts were analysed: Cohort 1 (n = 87) with advanced and Cohort 2 (n = 99) with completely resected melanoma. Patients were stratified by in the dynamics of CRP after ICI initiation: A doubling of baseline CRP within 30 days followed by at least a 30% drop within 3 months was classified as a CRP flare. If no doubling of CRP was reported, but a 30% drop within 3 months, patients were classified as CRP responders and all others as CRP non-responders. Analysed factors included clinical characteristics like S100B and LDH. Median follow-up was 1.5 and 1.7 years for Cohorts 1 and 2.RESULTS: In Cohort 1 CRP flare (n = 12), CRP responders (n = 43) and CRP non-responders (n = 32) with a progression-free survival (PFS) of 0.7, 0.6 and 0.2 years (p = 0.017) and an overall survival (OS) of 2.2, 1.5 and 1.0 years (p = 0.014), respectively. Multivariable Cox analysis showed an independent risk reduction of progression for CRP responders by 62% compared to CRP non-responders (p = 0.001). In Cohort 2 CRP flare (n = 13), CRP responders (n = 70) and CRP non-responders (n = 16) the log-rank analysis showed a significant difference between OS and recurrence-free survival (RFS) curves (p = 0.046 and p = 0.049).CONCLUSION: Early CRP kinetics could indicate a response to ICI with improved OS and RFS/PFS. CRP flare and CRP response indicating significantly improved outcomes compared to CRP non-responders.",
author = "Julian K{\"o}tt and Noah Zimmermann and Tim Zell and Isabel Heidrich and Glenn Geidel and Alessandra R{\"u}nger and Smit, {Daniel J.} and Myriam Merkle and Niousha Parnian and Inga Hansen and Inka Hoehne and Finn Abeck and Leopold Torster and Michael Weichenthal and Klaus Pantel and Schneider, {Stefan W} and Christoffer Gebhardt",
note = "{\textcopyright} 2024 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.",
year = "2024",
month = aug,
doi = "10.1111/jdv.19941",
language = "English",
volume = "38",
pages = "1575–1587",
journal = "J EUR ACAD DERMATOL",
issn = "0926-9959",
publisher = "Wiley-Blackwell",
number = "8",

}

RIS

TY - JOUR

T1 - C-reactive protein flare predicts response to checkpoint inhibitor treatment in melanoma

AU - Kött, Julian

AU - Zimmermann, Noah

AU - Zell, Tim

AU - Heidrich, Isabel

AU - Geidel, Glenn

AU - Rünger, Alessandra

AU - Smit, Daniel J.

AU - Merkle, Myriam

AU - Parnian, Niousha

AU - Hansen, Inga

AU - Hoehne, Inka

AU - Abeck, Finn

AU - Torster, Leopold

AU - Weichenthal, Michael

AU - Pantel, Klaus

AU - Schneider, Stefan W

AU - Gebhardt, Christoffer

N1 - © 2024 The Authors. Journal of the European Academy of Dermatology and Venereology published by John Wiley & Sons Ltd on behalf of European Academy of Dermatology and Venereology.

PY - 2024/8

Y1 - 2024/8

N2 - BACKGROUND: The treatment of melanoma has been revolutionized by the use of immune checkpoint inhibition (ICI), but many patients do not benefit. Furthermore, immune-related adverse events may occur during therapy. A predictive biomarker is needed to reliably identify patients benefitting. In lung, renal cell and bladder cancer early C-reactive protein (CRP) kinetics were shown to be a predictive biomarker for ICI.OBJECTIVE: Here, we investigate early CRP kinetics as predictive biomarker for ICI in melanoma patients.METHODS: Two independent prospectively collected cohorts were analysed: Cohort 1 (n = 87) with advanced and Cohort 2 (n = 99) with completely resected melanoma. Patients were stratified by in the dynamics of CRP after ICI initiation: A doubling of baseline CRP within 30 days followed by at least a 30% drop within 3 months was classified as a CRP flare. If no doubling of CRP was reported, but a 30% drop within 3 months, patients were classified as CRP responders and all others as CRP non-responders. Analysed factors included clinical characteristics like S100B and LDH. Median follow-up was 1.5 and 1.7 years for Cohorts 1 and 2.RESULTS: In Cohort 1 CRP flare (n = 12), CRP responders (n = 43) and CRP non-responders (n = 32) with a progression-free survival (PFS) of 0.7, 0.6 and 0.2 years (p = 0.017) and an overall survival (OS) of 2.2, 1.5 and 1.0 years (p = 0.014), respectively. Multivariable Cox analysis showed an independent risk reduction of progression for CRP responders by 62% compared to CRP non-responders (p = 0.001). In Cohort 2 CRP flare (n = 13), CRP responders (n = 70) and CRP non-responders (n = 16) the log-rank analysis showed a significant difference between OS and recurrence-free survival (RFS) curves (p = 0.046 and p = 0.049).CONCLUSION: Early CRP kinetics could indicate a response to ICI with improved OS and RFS/PFS. CRP flare and CRP response indicating significantly improved outcomes compared to CRP non-responders.

AB - BACKGROUND: The treatment of melanoma has been revolutionized by the use of immune checkpoint inhibition (ICI), but many patients do not benefit. Furthermore, immune-related adverse events may occur during therapy. A predictive biomarker is needed to reliably identify patients benefitting. In lung, renal cell and bladder cancer early C-reactive protein (CRP) kinetics were shown to be a predictive biomarker for ICI.OBJECTIVE: Here, we investigate early CRP kinetics as predictive biomarker for ICI in melanoma patients.METHODS: Two independent prospectively collected cohorts were analysed: Cohort 1 (n = 87) with advanced and Cohort 2 (n = 99) with completely resected melanoma. Patients were stratified by in the dynamics of CRP after ICI initiation: A doubling of baseline CRP within 30 days followed by at least a 30% drop within 3 months was classified as a CRP flare. If no doubling of CRP was reported, but a 30% drop within 3 months, patients were classified as CRP responders and all others as CRP non-responders. Analysed factors included clinical characteristics like S100B and LDH. Median follow-up was 1.5 and 1.7 years for Cohorts 1 and 2.RESULTS: In Cohort 1 CRP flare (n = 12), CRP responders (n = 43) and CRP non-responders (n = 32) with a progression-free survival (PFS) of 0.7, 0.6 and 0.2 years (p = 0.017) and an overall survival (OS) of 2.2, 1.5 and 1.0 years (p = 0.014), respectively. Multivariable Cox analysis showed an independent risk reduction of progression for CRP responders by 62% compared to CRP non-responders (p = 0.001). In Cohort 2 CRP flare (n = 13), CRP responders (n = 70) and CRP non-responders (n = 16) the log-rank analysis showed a significant difference between OS and recurrence-free survival (RFS) curves (p = 0.046 and p = 0.049).CONCLUSION: Early CRP kinetics could indicate a response to ICI with improved OS and RFS/PFS. CRP flare and CRP response indicating significantly improved outcomes compared to CRP non-responders.

U2 - 10.1111/jdv.19941

DO - 10.1111/jdv.19941

M3 - SCORING: Journal article

C2 - 38466133

VL - 38

SP - 1575

EP - 1587

JO - J EUR ACAD DERMATOL

JF - J EUR ACAD DERMATOL

SN - 0926-9959

IS - 8

ER -